Industrial - Machinery
Compare Stocks
5 / 10Stock Comparison
DCI vs ROP vs PH vs VRSK vs EMR
Revenue, margins, valuation, and 5-year total return — side by side.
Industrial - Machinery
Industrial - Machinery
Consulting Services
Industrial - Machinery
DCI vs ROP vs PH vs VRSK vs EMR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Industrial - Machinery | Industrial - Machinery | Industrial - Machinery | Consulting Services | Industrial - Machinery |
| Market Cap | $9.91B | $36.28B | $111.85B | $22.89B | $79.02B |
| Revenue (TTM) | $3.75B | $8.12B | $20.99B | $3.10B | $18.32B |
| Net Income (TTM) | $379M | $1.71B | $3.48B | $910M | $2.44B |
| Gross Margin | 34.4% | 69.4% | 37.2% | 67.4% | 52.7% |
| Operating Margin | 13.4% | 28.1% | 20.9% | 44.9% | 19.8% |
| Forward P/E | 21.6x | 15.7x | 28.2x | 22.5x | 21.7x |
| Total Debt | $730M | $9.30B | $9.64B | $5.04B | $13.76B |
| Cash & Equiv. | $180M | $297M | $467M | $2.18B | $1.54B |
DCI vs ROP vs PH vs VRSK vs EMR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Donaldson Company, … (DCI) | 100 | 181.2 | +81.2% |
| Roper Technologies,… (ROP) | 100 | 87.2 | -12.8% |
| Parker-Hannifin Cor… (PH) | 100 | 488.3 | +388.3% |
| Verisk Analytics, I… (VRSK) | 100 | 99.5 | -0.5% |
| Emerson Electric Co. (EMR) | 100 | 231.5 | +131.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: DCI vs ROP vs PH vs VRSK vs EMR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
DCI is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 36 yrs, beta 0.97, yield 1.3%
- Lower volatility, beta 0.97, Low D/E 50.2%, current ratio 1.93x
- Beta 0.97, yield 1.3%, current ratio 1.93x
ROP carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 12.3%, EPS growth -1.0%, 3Y rev CAGR 13.7%
- 12.3% revenue growth vs PH's -0.4%
- Lower P/E (15.7x vs 21.7x), PEG 1.63 vs 4.80
- Beta 0.43 vs EMR's 1.52, lower leverage
PH ranks third and is worth considering specifically for long-term compounding and valuation efficiency.
- 7.4% 10Y total return vs EMR's 206.6%
- PEG 1.18 vs EMR's 4.80
- +43.4% vs VRSK's -43.0%
VRSK is the #2 pick in this set and the best alternative if quality and efficiency is your priority.
- 29.3% margin vs DCI's 10.1%
- 16.7% ROA vs ROP's 5.0%, ROIC 33.0% vs 6.1%
EMR is the clearest fit if your priority is dividends.
- 1.5% yield, 37-year raise streak, vs PH's 0.7%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 12.3% revenue growth vs PH's -0.4% | |
| Value | Lower P/E (15.7x vs 21.7x), PEG 1.63 vs 4.80 | |
| Quality / Margins | 29.3% margin vs DCI's 10.1% | |
| Stability / Safety | Beta 0.43 vs EMR's 1.52, lower leverage | |
| Dividends | 1.5% yield, 37-year raise streak, vs PH's 0.7% | |
| Momentum (1Y) | +43.4% vs VRSK's -43.0% | |
| Efficiency (ROA) | 16.7% ROA vs ROP's 5.0%, ROIC 33.0% vs 6.1% |
DCI vs ROP vs PH vs VRSK vs EMR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
DCI vs ROP vs PH vs VRSK vs EMR — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ROP leads in 1 of 6 categories
VRSK leads 1 • PH leads 1 • EMR leads 1 • DCI leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — ROP and VRSK each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PH is the larger business by revenue, generating $21.0B annually — 6.8x VRSK's $3.1B. VRSK is the more profitable business, keeping 29.3% of every revenue dollar as net income compared to DCI's 10.1%. On growth, ROP holds the edge at +11.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $3.8B | $8.1B | $21.0B | $3.1B | $18.3B |
| EBITDAEarnings before interest/tax | $599M | $3.2B | $5.1B | $1.7B | $4.7B |
| Net IncomeAfter-tax profit | $379M | $1.7B | $3.5B | $910M | $2.4B |
| Free Cash FlowCash after capex | $350M | $2.6B | $3.7B | $1.1B | $3.1B |
| Gross MarginGross profit ÷ Revenue | +34.4% | +69.4% | +37.2% | +67.4% | +52.7% |
| Operating MarginEBIT ÷ Revenue | +13.4% | +28.1% | +20.9% | +44.9% | +19.8% |
| Net MarginNet income ÷ Revenue | +10.1% | +21.1% | +16.6% | +29.3% | +13.3% |
| FCF MarginFCF ÷ Revenue | +9.3% | +31.4% | +17.5% | +36.3% | +17.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +3.0% | +11.3% | +10.6% | +3.9% | +2.9% |
| EPS Growth (YoY)Latest quarter vs prior year | -1.3% | +59.1% | -4.2% | +4.8% | +28.2% |
Valuation Metrics
ROP leads this category, winning 5 of 7 comparable metrics.
Valuation Metrics
At 24.8x trailing earnings, ROP trades at a 29% valuation discount to EMR's 34.9x P/E. Adjusting for growth (PEG ratio), PH offers better value at 1.37x vs EMR's 7.73x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $9.9B | $36.3B | $111.8B | $22.9B | $79.0B |
| Enterprise ValueMkt cap + debt − cash | $10.5B | $45.3B | $121.0B | $25.7B | $91.2B |
| Trailing P/EPrice ÷ TTM EPS | 28.16x | 24.82x | 32.68x | 26.92x | 34.92x |
| Forward P/EPrice ÷ next-FY EPS est. | 21.62x | 15.66x | 28.15x | 22.47x | 21.70x |
| PEG RatioP/E ÷ EPS growth rate | 3.20x | 2.59x | 1.37x | 3.16x | 7.73x |
| EV / EBITDAEnterprise value multiple | 15.92x | 14.57x | 24.36x | 15.34x | 18.07x |
| Price / SalesMarket cap ÷ Revenue | 2.68x | 4.59x | 5.63x | 7.45x | 4.39x |
| Price / BookPrice ÷ Book value/share | 7.11x | 1.91x | 8.43x | 78.44x | 3.94x |
| Price / FCFMarket cap ÷ FCF | 29.14x | 14.55x | 33.48x | 19.20x | 29.63x |
Profitability & Efficiency
VRSK leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
VRSK delivers a 4.4% return on equity — every $100 of shareholder capital generates $4 in annual profit, vs $9 for ROP. ROP carries lower financial leverage with a 0.47x debt-to-equity ratio, signaling a more conservative balance sheet compared to VRSK's 16.26x. On the Piotroski fundamental quality scale (0–9), PH scores 8/9 vs VRSK's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +24.0% | +8.8% | +24.3% | +4.4% | +12.1% |
| ROA (TTM)Return on assets | +12.4% | +5.0% | +11.5% | +16.7% | +5.8% |
| ROICReturn on invested capital | +21.7% | +6.1% | +13.4% | +33.0% | +8.2% |
| ROCEReturn on capital employed | +25.6% | +7.7% | +17.8% | +39.6% | +10.0% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 6 | 8 | 5 | 7 |
| Debt / EquityFinancial leverage | 0.50x | 0.47x | 0.70x | 16.26x | 0.68x |
| Net DebtTotal debt minus cash | $550M | $9.0B | $9.2B | $2.9B | $12.2B |
| Cash & Equiv.Liquid assets | $180M | $297M | $467M | $2.2B | $1.5B |
| Total DebtShort + long-term debt | $730M | $9.3B | $9.6B | $5.0B | $13.8B |
| Interest CoverageEBIT ÷ Interest expense | 18.94x | 6.50x | 11.39x | 7.87x | 6.46x |
Total Returns (Dividends Reinvested)
PH leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PH five years ago would be worth $28,635 today (with dividends reinvested), compared to $8,255 for ROP. Over the past 12 months, PH leads with a +43.4% total return vs VRSK's -43.0%. The 3-year compound annual growth rate (CAGR) favors PH at 39.3% vs ROP's -7.6% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -4.2% | -18.5% | -0.7% | -20.7% | +4.3% |
| 1-Year ReturnPast 12 months | +31.6% | -38.0% | +43.4% | -43.0% | +30.4% |
| 3-Year ReturnCumulative with dividends | +39.5% | -21.0% | +170.5% | -14.5% | +75.9% |
| 5-Year ReturnCumulative with dividends | +40.0% | -17.5% | +186.4% | +1.8% | +59.5% |
| 10-Year ReturnCumulative with dividends | +194.5% | +115.0% | +737.4% | +137.1% | +206.6% |
| CAGR (3Y)Annualised 3-year return | +11.7% | -7.6% | +39.3% | -5.1% | +20.7% |
Risk & Volatility
Evenly matched — PH and VRSK each lead in 1 of 2 comparable metrics.
Risk & Volatility
VRSK is the less volatile stock with a -0.04 beta — it tends to amplify market swings less than EMR's 1.52 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PH currently trades 85.6% from its 52-week high vs VRSK's 54.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.97x | 0.39x | 1.00x | -0.08x | 1.57x |
| 52-Week HighHighest price in past year | $112.84 | $584.03 | $1034.96 | $322.92 | $165.15 |
| 52-Week LowLowest price in past year | $65.72 | $313.86 | $616.56 | $161.70 | $108.37 |
| % of 52W HighCurrent price vs 52-week peak | +76.1% | +60.3% | +85.6% | +54.1% | +85.4% |
| RSI (14)Momentum oscillator 0–100 | 49.4 | 43.6 | 42.6 | 39.5 | 61.3 |
| Avg Volume (50D)Average daily shares traded | 639K | 1.2M | 710K | 1.9M | 2.8M |
Analyst Outlook
EMR leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: DCI as "Hold", ROP as "Buy", PH as "Buy", VRSK as "Hold", EMR as "Buy". Consensus price targets imply 32.4% upside for VRSK (target: $231) vs 14.3% for EMR (target: $161). For income investors, EMR offers the higher dividend yield at 1.49% vs PH's 0.75%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Hold | Buy |
| Price TargetConsensus 12-month target | $103.20 | $457.64 | $1042.08 | $231.25 | $161.31 |
| # AnalystsCovering analysts | 14 | 23 | 38 | 25 | 41 |
| Dividend YieldAnnual dividend ÷ price | +1.3% | +0.9% | +0.7% | +1.0% | +1.5% |
| Dividend StreakConsecutive years of raises | 36 | 12 | 33 | 7 | 37 |
| Dividend / ShareAnnual DPS | $1.10 | $3.29 | $6.61 | $1.81 | $2.10 |
| Buyback YieldShare repurchases ÷ mkt cap | +3.3% | +1.4% | +1.6% | +2.7% | +1.6% |
ROP leads in 1 of 6 categories (Valuation Metrics). VRSK leads in 1 (Profitability & Efficiency). 2 tied.
DCI vs ROP vs PH vs VRSK vs EMR: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is DCI or ROP or PH or VRSK or EMR a better buy right now?
For growth investors, Roper Technologies, Inc.
(ROP) is the stronger pick with 12. 3% revenue growth year-over-year, versus -0. 4% for Parker-Hannifin Corporation (PH). Roper Technologies, Inc. (ROP) offers the better valuation at 24. 8x trailing P/E (15. 7x forward), making it the more compelling value choice. Analysts rate Roper Technologies, Inc. (ROP) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — DCI or ROP or PH or VRSK or EMR?
On trailing P/E, Roper Technologies, Inc.
(ROP) is the cheapest at 24. 8x versus Emerson Electric Co. at 34. 9x. On forward P/E, Roper Technologies, Inc. is actually cheaper at 15. 7x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Parker-Hannifin Corporation wins at 1. 18x versus Emerson Electric Co. 's 4. 80x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — DCI or ROP or PH or VRSK or EMR?
Over the past 5 years, Parker-Hannifin Corporation (PH) delivered a total return of +186.
4%, compared to -17. 5% for Roper Technologies, Inc. (ROP). Over 10 years, the gap is even starker: PH returned +732. 6% versus ROP's +109. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — DCI or ROP or PH or VRSK or EMR?
By beta (market sensitivity over 5 years), Verisk Analytics, Inc.
(VRSK) is the lower-risk stock at -0. 08β versus Emerson Electric Co. 's 1. 57β — meaning EMR is approximately -1966% more volatile than VRSK relative to the S&P 500. On balance sheet safety, Roper Technologies, Inc. (ROP) carries a lower debt/equity ratio of 47% versus 16% for Verisk Analytics, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — DCI or ROP or PH or VRSK or EMR?
By revenue growth (latest reported year), Roper Technologies, Inc.
(ROP) is pulling ahead at 12. 3% versus -0. 4% for Parker-Hannifin Corporation (PH). On earnings-per-share growth, the picture is similar: Parker-Hannifin Corporation grew EPS 24. 2% year-over-year, compared to -9. 8% for Donaldson Company, Inc.. Over a 3-year CAGR, ROP leads at 13. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — DCI or ROP or PH or VRSK or EMR?
Verisk Analytics, Inc.
(VRSK) is the more profitable company, earning 29. 6% net margin versus 9. 9% for Donaldson Company, Inc. — meaning it keeps 29. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VRSK leads at 44. 6% versus 15. 1% for DCI. At the gross margin level — before operating expenses — ROP leads at 69. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is DCI or ROP or PH or VRSK or EMR more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Parker-Hannifin Corporation (PH) is the more undervalued stock at a PEG of 1. 18x versus Emerson Electric Co. 's 4. 80x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Roper Technologies, Inc. (ROP) trades at 15. 7x forward P/E versus 28. 2x for Parker-Hannifin Corporation — 12. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for VRSK: 32. 4% to $231. 25.
08Which pays a better dividend — DCI or ROP or PH or VRSK or EMR?
All stocks in this comparison pay dividends.
Emerson Electric Co. (EMR) offers the highest yield at 1. 5%, versus 0. 7% for Parker-Hannifin Corporation (PH).
09Is DCI or ROP or PH or VRSK or EMR better for a retirement portfolio?
For long-horizon retirement investors, Verisk Analytics, Inc.
(VRSK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 08), 1. 0% yield, +133. 5% 10Y return). Emerson Electric Co. (EMR) carries a higher beta of 1. 57 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (VRSK: +133. 5%, EMR: +207. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between DCI and ROP and PH and VRSK and EMR?
Both stocks operate in the Industrials sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.